202 related articles for article (PubMed ID: 37981695)
21. Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.
Zhang Q; Zhu X; Liu B; Zhang Y; Xiao Y
Front Immunol; 2023; 14():1127868. PubMed ID: 37006273
[TBL] [Abstract][Full Text] [Related]
22. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
23.
Chen L; Mu W; Gu J; Xiao M; Huang L; Zheng M; Li C; Xiao Y; Zhou J; Long X
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34066756
[TBL] [Abstract][Full Text] [Related]
24. [Clinical and prognostic values of TP53 mutation in patients with B-lineage acute lymphoblastic leukemia].
Du YY; Lyu KK; Xu MM; Yao WQ; Kang HZ; Han Y; Tang XW; Ma X; Wu XJ; He XF; Wu DP; Liu YJ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):396-401. PubMed ID: 34218582
[No Abstract] [Full Text] [Related]
25. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
26. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
[TBL] [Abstract][Full Text] [Related]
27. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience.
Ghafouri S; Fenerty K; Schiller G; de Vos S; Eradat H; Timmerman J; Larson S; Mead M
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):861-872. PubMed ID: 34389271
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis.
Al-Mansour M; Al-Foheidi M; Ibrahim E
Mol Clin Oncol; 2020 Oct; 13(4):33. PubMed ID: 32789017
[TBL] [Abstract][Full Text] [Related]
29. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
Cao Y; Lu W; Sun R; Jin X; Cheng L; He X; Wang L; Yuan T; Lyu C; Zhao M
Front Oncol; 2019; 9():767. PubMed ID: 31482064
[TBL] [Abstract][Full Text] [Related]
31. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
[TBL] [Abstract][Full Text] [Related]
32. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
33. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
[TBL] [Abstract][Full Text] [Related]
34. CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.
Cheng Q; Tan J; Liu R; Kang L; Zhang Y; Wang E; Li Y; Zhang J; Xiao H; Xu N; Li M; Yu L; Li X
Cytotherapy; 2022 Oct; 24(10):1026-1034. PubMed ID: 35691818
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era.
Xie J; Wu A; Liao L; Nastoupil LJ; Du EX; Noman A; Chen L
Curr Med Res Opin; 2021 Oct; 37(10):1789-1798. PubMed ID: 34344238
[TBL] [Abstract][Full Text] [Related]
36. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Gauthier J; Gazeau N; Hirayama AV; Hill JA; Wu V; Cearley A; Perkins P; Kirk A; Shadman M; Chow VA; Gopal AK; Hodges Dwinal A; Williamson S; Myers J; Chen A; Nagle S; Hayes-Lattin B; Schachter L; Maloney DG; Turtle CJ; Sorror ML; Maziarz RT
Blood; 2022 Jun; 139(26):3722-3731. PubMed ID: 35439295
[TBL] [Abstract][Full Text] [Related]
37. Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective.
Sheikh IN; Elgehiny A; Ragoonanan D; Mahadeo KM; Nieto Y; Khazal S
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740580
[TBL] [Abstract][Full Text] [Related]
38. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
39. CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
Ostojska M; Nowak E; Twardowska J; Lejman M; Zawitkowska J
J Pers Med; 2023 Nov; 13(11):. PubMed ID: 38003910
[TBL] [Abstract][Full Text] [Related]
40. Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
Kanwal B
Cureus; 2021 Jul; 13(7):e16307. PubMed ID: 34277304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]